Adverse effects of tenofovir use in HIV-infected pregnant women and their infants

Annals of Pharmacotherapy

Volumn 42, Issue 11, 2008, Pages 1581-1585

  Nurutdinova, Diana ^a,b   Onen, Nur F ^d   Hayes, Ericka ^c   Mondy, Kristin ^c   Overton, E Turner ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NONE

Author keywords

HIV; Pregnancy; Tenofovir

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PHOSPHONIC ACIDS; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 55949090251     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L083     Document Type: Article

References (15)

1. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004;292:191-201.
2. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004;43:1071-87.
3. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. October 12, 2006, 1-65. http://aidsinfo.nih.gov/ contentfiles/PerinatalGL.pdf (accessed 2008 May 9).
4. The antiretroviral pregnancy registry. www.apregistry.com/forms/ interim_report.pdf (accessed 2008 May 9).
5. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002;29:207-20.
6. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:323-33.
7. Van Rompay KK, Marthas ML, Lifson JD, et al. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 1998;14:761-73.
8. Wilson TE, Gore ME, Greenblatt R, et al. Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health 2004; 94:1141-6.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
10. Namale L, Zalwngo E, Chidziva E, et al. Pregnancy and pregnancy outcome among women in the DART Trial. Presented at: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
11. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomized trial. Lancet 2007;370: 1698-705. Epub 7 Nov 2007.
12. Overton ET, Sungkanuparph S, Nurutdinova D, Powderly WG. Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy (letter). AIDS 2005;19:1439.
13. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005;19:63-7.
14. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004;48:124-9.
15. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006;118:e711-8.